IMV (IMV) Stock Price, News & Analysis

Company Overview

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 15,761 shs
• Average Volume: 56,822 shs
• Market Capitalization: C$13.12 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Computer Hardware
• Current Symbol: TSE:IMV
• CIK: N/A
• Web: www.imvaccine.com
• Phone: +1-902-4921819
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): C($6.11)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -C$37.99 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -508.58%
• Return on Assets: -61.78%

Debt

• Debt-to-Equity Ratio: 1,231.01
• Current Ratio: 2.93
• Quick Ratio: 2.32

Sales & Book Value

• Annual Sales: C$23 thousand
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 1.61
• Book Value: C($0.69) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 11,710,000
• Free Float: N/A
• Market Cap: C$13.12 million
• Optionable: Not Optionable
• Beta: 1.52